The Insulin Like Growth Factor and Binding Protein Family: Novel Therapeutic Targets in Obesity & Diabetes

Overview

Journal Mol Metab

Specialty Cell Biology

Date 2018 Nov 6

PMID 30392760

Citations 87

Authors

Natalie J Haywood

Thomas A Slater

Connor J Matthews

Stephen B Wheatcroft

Affiliations

Soon will be listed here.

Abstract

Background: Recent changes in nutrition and lifestyle have provoked an unprecedented increase in the prevalence of obesity and metabolic disorders. Recognition of the adverse effects on health has prompted intense efforts to understand the molecular determinants of insulin sensitivity and dysglycemia. In many respects, actions of insulin-like growth factors (IGFs) mirror those of insulin in metabolic regulation. Unlike insulin, however, the bioactivity of IGFs is regulated by a family of seven high-affinity binding proteins (IGFBPs) which confer temporospatial modulation with implications for metabolic homeostasis. In addition, evidence is accumulating that IGF-independent actions of certain of the IGFBPs can directly modulate insulin sensitivity.

Scope Of Review: In this review, we discuss the experimental data indicating a critical role for IGF/IGFBP axis in metabolic regulation. We highlight key discoveries through which IGFBPs have emerged as biomarkers or putative therapeutic targets in obesity and diabetes.

Major Conclusions: Growing evidence suggests that several components of the IGF-IGFBP system could be explored for therapeutic potential in metabolic disorders. Both IGFBP-1 and IGFBP-2 have been favorably linked with insulin sensitivity in humans and preclinical data implicate direct involvement in the molecular regulation of insulin signaling and adiposity respectively. Further studies are warranted to evaluate clinical translation of these findings.

Citing Articles

Deep phenotyping of patients with MASLD upon high-intensity interval training.

Houttu V, Boulund U, Troelstra M, Csader S, Stols-Goncalves D, Mak A JHEP Rep. 2025; 7(3):101289.

PMID: 40051412 PMC: 11883402. DOI: 10.1016/j.jhepr.2024.101289.

Identification of plasma proteomic markers underlying polygenic risk of type 2 diabetes and related comorbidities.

Loesch D, Garg M, Matelska D, Vitsios D, Jiang X, Ritchie S Nat Commun. 2025; 16(1):2124.

PMID: 40032831 PMC: 11876343. DOI: 10.1038/s41467-025-56695-z.

Associations between accurate measures of adiposity and fitness, blood proteins, and insulin sensitivity among South Asians and Europeans.

Kho P, Stell L, Jimenez S, Zanetti D, Panyard D, Watson K Front Endocrinol (Lausanne). 2025; 15:1492778.

PMID: 39902167 PMC: 11788178. DOI: 10.3389/fendo.2024.1492778.

The landscape of plasma proteomic links to human organ imaging.

Fan Z, Chirinos J, Yang X, Shu J, Li Y, OBrien J medRxiv. 2025; .

PMID: 39867388 PMC: 11759249. DOI: 10.1101/2025.01.14.25320532.

Paracrine role of endothelial IGF-1 receptor in depot-specific adipose tissue adaptation in male mice.

Luk C, Bridge K, Warmke N, Simmons K, Drozd M, Moran A Nat Commun. 2025; 16(1):170.

PMID: 39747815 PMC: 11696296. DOI: 10.1038/s41467-024-54669-1.

References

Attia N, Tamborlane W, Heptulla R, Maggs D, Grozman A, Sherwin R . The metabolic syndrome and insulin-like growth factor I regulation in adolescent obesity. J Clin Endocrinol Metab. 1998; 83(5):1467-71. DOI: 10.1210/jcem.83.5.4827. View

Gleason C, Ning Y, Cominski T, Gupta R, Kaestner K, Pintar J . Role of insulin-like growth factor-binding protein 5 (IGFBP5) in organismal and pancreatic beta-cell growth. Mol Endocrinol. 2009; 24(1):178-92. PMC: 2802899. DOI: 10.1210/me.2009-0167. View

Gokulakrishnan K, Velmurugan K, Ganesan S, Mohan V . Circulating levels of insulin-like growth factor binding protein-1 in relation to insulin resistance, type 2 diabetes mellitus, and metabolic syndrome (Chennai Urban Rural Epidemiology Study 118). Metabolism. 2011; 61(1):43-6. DOI: 10.1016/j.metabol.2011.05.014. View

Bang P, Nygren J, Carlsson-Skwirut C, Thorell A, Ljungqvist O . Postoperative induction of insulin-like growth factor binding protein-3 proteolytic activity: relation to insulin and insulin sensitivity. J Clin Endocrinol Metab. 1998; 83(7):2509-15. DOI: 10.1210/jcem.83.7.4916. View

Williams A, Kang L, Wasserman D . The extracellular matrix and insulin resistance. Trends Endocrinol Metab. 2015; 26(7):357-66. PMC: 4490038. DOI: 10.1016/j.tem.2015.05.006. View

Imrie H, Abbas A, Viswambharan H, Rajwani A, Cubbon R, Gage M . Vascular insulin-like growth factor-I resistance and diet-induced obesity. Endocrinology. 2009; 150(10):4575-82. DOI: 10.1210/en.2008-1641. View

Saydah S, Ballard-Barbash R, Potischman N . Association of metabolic syndrome with insulin-like growth factors among adults in the US. Cancer Causes Control. 2009; 20(8):1309-16. DOI: 10.1007/s10552-009-9351-x. View

Zenobi P, Graf S, Ursprung H, FROESCH E . Effects of insulin-like growth factor-I on glucose tolerance, insulin levels, and insulin secretion. J Clin Invest. 1992; 89(6):1908-13. PMC: 295890. DOI: 10.1172/JCI115796. View

Heald A, Cruickshank J, Riste L, Cade J, Anderson S, Greenhalgh A . Close relation of fasting insulin-like growth factor binding protein-1 (IGFBP-1) with glucose tolerance and cardiovascular risk in two populations. Diabetologia. 2001; 44(3):333-9. DOI: 10.1007/s001250051623. View

10.

Regan F, Williams R, McDonald A, Umpleby A, Acerini C, ORahilly S . Treatment with recombinant human insulin-like growth factor (rhIGF)-I/rhIGF binding protein-3 complex improves metabolic control in subjects with severe insulin resistance. J Clin Endocrinol Metab. 2010; 95(5):2113-22. DOI: 10.1210/jc.2009-2088. View

11.

Song Z, Dai X, Yu H, Luo Q, Zhang H, Wu L . Increased Serum IGFBP-1 and Reduced Insulin Resistance After Roux-En-Y Gastric Bypass in Chinese Patients with Type 2 Diabetes: a 6-Month Follow-Up. Obes Surg. 2018; 28(10):3165-3171. DOI: 10.1007/s11695-018-3242-8. View

12.

Wild S, Roglic G, Green A, Sicree R, King H . Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004; 27(5):1047-53. DOI: 10.2337/diacare.27.5.1047. View

13.

Gaunt T, Cooper J, Miller G, Day I, ODell S . Positive associations between single nucleotide polymorphisms in the IGF2 gene region and body mass index in adult males. Hum Mol Genet. 2001; 10(14):1491-501. DOI: 10.1093/hmg/10.14.1491. View

14.

Rajpathak S, McGinn A, Strickler H, Rohan T, Pollak M, Cappola A . Insulin-like growth factor-(IGF)-axis, inflammation, and glucose intolerance among older adults. Growth Horm IGF Res. 2007; 18(2):166-73. PMC: 2492581. DOI: 10.1016/j.ghir.2007.08.004. View

15.

Booth G, Kapral M, Fung K, Tu J . Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study. Lancet. 2006; 368(9529):29-36. DOI: 10.1016/S0140-6736(06)68967-8. View

16.

Mur C, Valverde A, Kahn C, Benito M . Increased insulin sensitivity in IGF-I receptor--deficient brown adipocytes. Diabetes. 2002; 51(3):743-54. DOI: 10.2337/diabetes.51.3.743. View

17.

Succurro E, Andreozzi F, Marini M, Lauro R, Hribal M, Perticone F . Low plasma insulin-like growth factor-1 levels are associated with reduced insulin sensitivity and increased insulin secretion in nondiabetic subjects. Nutr Metab Cardiovasc Dis. 2009; 19(10):713-9. DOI: 10.1016/j.numecd.2008.12.011. View

18.

Slaaby R, Schaffer L, Lautrup-Larsen I, Andersen A, Shaw A, Mathiasen I . Hybrid receptors formed by insulin receptor (IR) and insulin-like growth factor I receptor (IGF-IR) have low insulin and high IGF-1 affinity irrespective of the IR splice variant. J Biol Chem. 2006; 281(36):25869-74. DOI: 10.1074/jbc.M605189200. View

19.

Jehle P, Jehle D, Mohan S, Bohm B . Serum levels of insulin-like growth factor system components and relationship to bone metabolism in Type 1 and Type 2 diabetes mellitus patients. J Endocrinol. 1998; 159(2):297-306. DOI: 10.1677/joe.0.1590297. View

20.

Gu T, Gu H, Hilding A, Sjoholm L, Ostenson C, Ekstrom T . Increased DNA methylation levels of the insulin-like growth factor binding protein 1 gene are associated with type 2 diabetes in Swedish men. Clin Epigenetics. 2013; 5(1):21. PMC: 3843565. DOI: 10.1186/1868-7083-5-21. View